{"id":14300,"date":"2016-02-05T11:04:53","date_gmt":"2016-02-05T10:04:53","guid":{"rendered":"https:\/\/www.mc-narkus.de\/?page_id=14300"},"modified":"2020-08-12T17:56:24","modified_gmt":"2020-08-12T15:56:24","slug":"contribution-to-allergy","status":"publish","type":"page","link":"https:\/\/www.mc-narkus.de\/en\/contribution-to-allergy\/","title":{"rendered":"Contribution to Allergy"},"content":{"rendered":"

References<\/span><\/h2>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>
List of Publications<\/span><\/a><\/div>
<\/div><\/div><\/div>
Contribution to Allergy<\/span><\/a><\/div>
<\/div><\/div><\/div>
Best of ERS<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div>

Contribution to Allergy (2004 – 2015)<\/h2>\n<\/div>
<\/div>
<\/div><\/div>
<\/div>
<\/div><\/div><\/div>

<\/i><\/i><\/span>(1) Development of the first validated Symptom-Medication-Score in Allergy: <\/span><\/a><\/h4><\/div>
\n

Annemie Narkus. Validation and suitability of the Allergy-Control-SCORE (ACS\u00a9<\/sup>). 14th <\/sup>International Paul-Ehrlich-Seminar 2014, Bad Nauheim. www.pei.de\/ipes2014.
\nwww.pei.de\/ipes2014<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(2) Results of the first clinical trial with a recombinant Bet v1 FV: <\/span><\/a><\/h4><\/div>
\n

Klimek L, Bachert C, Lukat K F, Pfaar O, Meyer H, Narkus A. Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy 2015; 5:28. doi: 10.1186\/s13601-015-0071-x. eCollection@2015.: 28-0071.
\n<\/em>www.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(3) Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters:<\/span><\/a><\/h4><\/div>
\n

H\u00e4fner D, G\u00f6dicke V, Narkus A. Allergen specific immunotherapy has no influence on standard chemistry and hematology laboratory parameters in clinical studies. Clin Transl Allergy 2014; 4(18): 1-14.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(4) Results of the first dose-range finding study with a recombinant Bet v1 FV:<\/span><\/a><\/h4><\/div>
\n

Meyer W, Narkus A, Salapatek A M, H\u00e4fner D. Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber. Allergy 2013; 68(6): 724-731.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(5) The Placebo effect in Allergen Specific Immunotherapy (AIT):<\/span><\/a><\/h4><\/div>
\n

Narkus A, Lehnigk U, Haefner D, Klinger R, Pfaar O, Worm M. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013; 3(1): 42.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(6) The first prospective validation of a rhino-conjunctivitis symptom-medication-score: <\/span><\/a><\/h4><\/div>
\n

H\u00e4fner D, Reich K, Zschocke I, Lotzin A, Meyer H, Kettner J, Narkus A. Prospective validation of the „rhino conjunctivitis allergy-control-SCORE(c)“ (RC-ACS(c)). Clin Transl Allergy 2012; 2(17): 1-8.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(7) The first prospective validation of an allergy symptom-medication-score:<\/span><\/a><\/h4><\/div>
\n

H\u00e4fner D, Reich K, Matricardi P M, Meyer H, Kettner J, Narkus A. Prospective validation of ‚Allergy-Control-SCORE(TM) ‚: a novel symptom-medication score for clinical trials. Allergy 2011; 66(5): 629-636.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(8) A comparison of subcutaneous immunotherapy (SCIT) with anti-symptomatic treatment in seasonal allergic rhinitis: <\/span><\/a><\/h4><\/div>
\n

Matricardi P M, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses. J Allergy Clin Immunol 2011; 128(4): 791-799.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(9) Results of first clinical trials with recombinant birch and grass pollen immunotherapy:<\/span><\/a><\/h4><\/div>
Narkus A, Kniest F, Menzel A, Meyer H, Sprung V. Clinical trials with recombinant allergens – three perspectives: industry. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2008; 96: 270-278.<\/div><\/div><\/div>

<\/i><\/i><\/span>(10) Strategies for recombinant allergen vaccines:<\/span><\/a><\/h4><\/div>
\n

Cromwell O, Fiebig H, Suck R, Kahlert H, Nandy A, Kettner J, Narkus A. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin N Amer 2006; 26(2): 261-281.<\/p>\n

www.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(11) Clinical evaluation of recombinant allergens:<\/span><\/a><\/h4><\/div>
Cromwell O, Narkus A. Clinical evaluation of recombinant allergens. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2006; 95: 195-200.<\/div><\/div><\/div>

<\/i><\/i><\/span>(12) Efficacy and safety of preseasonal-specific immunotherapy with an hypo-allergenic high dose six-grass pollen allergoid:<\/span><\/a><\/h4><\/div>
\n

Corrigan C J, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60(6): 801-807.
\nwww.pubmed.de\/data\/nlm.link.html<\/a><\/p>\n<\/div><\/div><\/div>

<\/i><\/i><\/span>(13) Efficacy and safety of specific immunotherapy with an hypo-allergenic high dose mite allergoid:<\/span><\/a><\/h4><\/div>
Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Spezifische Immuntherapie mit einem neu entwickelten Hausstaubmilbenallergoid (Acaroid\u00ae). Eine doppelblinde, plazebokontrollierte Studie \u00fcber 2 Jahre mit einem Fortsetzungsjahr. Allergo J 2005; 14(5): 337-343.<\/div><\/div><\/div>

<\/i><\/i><\/span>(14) Cluster immunotherapy:<\/span><\/a><\/h4><\/div>
Hansen I, H\u00f6rmann K, Klimek L, Kettner J, Narkus A. Cluster-Immuntherapie bei allergischer Rhinokonjunktivitis und Asthma bronchiale: Sicherheit der Initialtherapie mit Novo-Helisen Depot. Allergologie 2004; 27(12): 477-483.<\/div><\/div><\/div>

<\/i><\/i><\/span>(15) The role of storage mites:<\/span><\/a><\/h4><\/div>
Kroidl R F, Brockhausen G, Narkus A. Vorratsmilben sind beruflich relevante Allergene in der Landwirtschaft. Allergologie 1994; 20(1): 46-50.<\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-14300","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/comments?post=14300"}],"version-history":[{"count":12,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14300\/revisions"}],"predecessor-version":[{"id":14396,"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/pages\/14300\/revisions\/14396"}],"wp:attachment":[{"href":"https:\/\/www.mc-narkus.de\/en\/wp-json\/wp\/v2\/media?parent=14300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}